Tag Archive for: DaltonTx

DaltonTx appoints Melissa Landon as Chief Commercial Officer to drive commercial growth and strategic partnerships

Dr Landon brings 20+ years of experience in the application of AI/ ML to drug discovery She joins DaltonTx to drive adoption of DaltonTx platform across pharma, biotech and CROs London, UK – 12 November 2026 – DaltonTx, the decision engine for drug discovery, today announced the appointment of Melissa Landon, Ph.D., as Chief Commercial […]

DaltonTx awarded grant to accelerate AI-powered tuberculosis drug discovery

Funding from the Gates Foundation supports development of open-access AI models, workflows and datasets to help researchers identify new tuberculosis (TB) targets for faster and more cost-effective drug discovery Project will analyse hundreds of essential TB proteins at proteome scale, demonstrating Dalton’s ability to tackle complex scientific challenges Collaboration with Ersilia will make findings accessible […]

DaltonTx, the decision engine for drug discovery, launches advanced AI-powered antibody discovery platform

New capabilities enable researchers to analyse, characterise and prioritise antibody candidates at scale Integrated AI models and workflows support better informed decisions about which antibodies to progress experimentally London, UK – 1 October 2026 – DaltonTx, the decision engine for drug discovery, today announced the launch of advanced antibody discovery capabilities within the Dalton platform. […]

Weekly Roundup: Conference Countdown and a Busy Autumn Ahead

European Commission grants marketing authorisation for NEZGLYAL® (leriglitazone), the first pharmacological treatment approved for cerebral Adrenoleukodystrophy (cALD), a rare neurodegenerative disease  Neuraxpharm Group announced that the European Commission (EC) has granted marketing authorisation under exceptional circumstances for NEZGLYAL® (leriglitazone), an orally bioavailable, brain penetrating, selective PPAR gamma agonist, as a treatment for male cALD patients, […]

Weekly Roundup: Biotech in bloom this June

The heatwave has been replaced by heavy showers, but June is looking bright for our clients, with huge congratulations to Ona Therapeutics for its $86.6M Series B financing and to DaltonTx  for the launch of its AI-enabled drug discovery platform. Dr. Hans Eriksson is joining FundaMental Pharma’s team as CMO and Renée Aguiar-Lucander participated in […]

© Optimum Strategic Communications.